SANTA CRUZ BIOTECHNOLOGY, INC.

HMG-1 siRNA (h): sc-37982

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

High mobility group (HMG) proteins 1 and 2 are ubiquitous non-histone components of chromatin. Evidence suggests that the binding of HMG proteins to DNA induces alterations in the DNA architecture including DNA bending and unwinding of the helix. HMG proteins synergize with Oct-2, members of the NFκB family, ATF-2 and c-Jun to activate transcription. Other studies indicate that phosphorylation of HMG protein is required to stimulate the transcriptional activity of the protein. Human HMG-1 and HMG-2 both contain two DNA-binding domains, termed HMG boxes. HMG proteins bind single-stranded DNA but induce conformational changes in double-stranded DNA alone.

CHROMOSOMAL LOCATION

Genetic locus: HMGB1 (human) mapping to 13q12.3.

PRODUCT

HMG-1 siRNA (h) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 µM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see HMG-1 shRNA Plasmid (h): sc-37982-SH and HMG-1 shRNA (h) Lentiviral Particles: sc-37982-V as alternate gene silencing products.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 µl of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 µl of RNAse-free water makes a 10 µM solution in a 10 µM Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

HMG-1 siRNA (h) is recommended for the inhibition of HMG-1 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

GENE EXPRESSION MONITORING

HMG-1 (D-3): sc-518191 is recommended as a control antibody for monitoring of HMG-1 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor HMG-1 gene expression knockdown using RT-PCR Primer: HMG-1 (h)-PR: sc-37982-PR (20 µl, 491 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

SELECT PRODUCT CITATIONS

1. El Gazzar, M., et al. 2009. Chromatin-specific remodeling by HMGB1 and linker Histone H1 silences proinflammatory genes during endotoxin tolerance. Mol. Cell. Biol. 29: 1959-1971.
2. Zhang, L., et al. 2015. Protective roles of pulmonary rehabilitation mixture in experimental pulmonary fibrosis *in vitro* and *in vivo*. Braz. J. Med. Biol. Res. 48: 545-552.
3. Kim, M., et al. 2016. GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy. Autophagy 13: 149-168.
4. Chung, H.W. and Lim, J.B. 2017. High-mobility group box-1 contributes tumor angiogenesis under interleukin-8 mediation during gastric cancer progression. Cancer Sci. 108: 1594-1601.
5. Chung, H.W. and Lim, J.B. 2017. High-mobility group box-1 contributes tumor angiogenesis under interleukin-8 mediation during gastric cancer progression. Cancer Sci. 108: 1594-1601.
6. Ji, Y., et al. 2018. Indinavir plus methylprednisolone ameliorates experimental acute lung injury *in vitro* and *in vivo*. Shock 49: 196-204.
7. Cheng, P., et al. 2018. High mobility group Box 1 (HMGB1) predicts invasion and poor prognosis of glioblastoma multiforme via activating Akt signaling in an autocrine pathway. Med. Sci. Monit. 24: 8916-8924.
8. Yang, Y., et al. 2020. HMGB1 mediates lipopolysaccharide-induced inflammation via interacting with GPX4 in colon cancer cells. Cancer Cell Int. 20: 205.
9. Wang, X., et al. 2021. Astragaloside IV antagonizes M2 phenotype macrophage polarization-evoked ovarian cancer cell malignant progression by suppressing the HMGB1-TLR4 axis. Mol. Immunol. 130: 113-121.
10. Jung, A.R., et al. 2021. HMGB1 promotes tumor progression and invasion through HMGB1/TNFR1/NFκB axis in castration-resistant prostate cancer. Am. J. Cancer Res. 11: 2215-2227.
11. Zhou, Q., et al. 2021. Endothelial specific deletion of HMGB1 increases blood pressure and retards ischemia recovery through eNOS and ROS pathway in mice. Redox Biol. 41: 101890.

RESEARCH USE

For research use only, not for use in diagnostic procedures.